Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical, Inc.filedCriticalBoston Biomedical, Inc.
Publication of HK1230963A1publicationCriticalpatent/HK1230963A1/en
The invention provides thiazole-substituted indolin-2-ones as inhibitors of cancer stem cell pathway kinases (CSCPK) and related kinases, and methods of using these compounds, to treat subjects in need thereof.
HK17104737.1A2014-01-272015-01-26Novel methods for treating cancer
HK1230963A1
(en)